Ceralasertib - OmicsDI

Show results for

Unknown (36)
Genomics (13)
Transcriptomics (7)
Proteomics (4)
Clinical (1)

Organisms

Mus musculus (5)
Andropogon gerardi (3)
Bacteria (3)
Borrelia (3)
Botrytis cinerea (3)
Candida albicans (3)
Canis lupus familiaris (3)
Clostridium perfringens (3)
Cnidaria (3)
Eukaryota (3)
Fasciola (3)
Fungi (3)
Hepatitis B virus (3)
Human betaherpesvirus 5 (3)
Influenza C virus (3)
Japanese encephalitis virus group (3)
Miscanthus x giganteus (3)
Mycobacterium tuberculosis (3)
Orthoflavivirus (3)
Panicum virgatum (3)
Platyhelminthes (3)
Pseudomonas aeruginosa AES-1R (3)
Rickettsia (3)
Saccharomyces cerevisiae (3)
Schizosaccharomyces pombe (3)
Severe acute respiratory syndrome coronavirus 2 (3)
Shigella (3)
Sorghastrum nutans (3)
Streptococcus pneumoniae (3)
Homo sapiens (2)

Organisms

Homo sapiens (4)
Mus musculus (1)

Repository

ENA (13)
biostudies-arrayexpress (5)
pride (3)
geo (2)
MassIVE (1)

Tissue

Cell culture (2)
Myeloid cell (1)

Disease

Carcinoma (1)
Acute leukemia (1)
Neuroblastoma (1)

Technology Type

Mass Spectrometry (3)
Affinity purification coupled with mass spectrometry proteomics (1)
Bottom-up proteomics (1)
Shotgun proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (5)
Orbitrap Exploris 480 (1)

Publication Date

2025 (3)
2024 (3)
2023 (3)
2026 (2)

First Public Date

2024 (4)
2025 (3)
2026 (2)
2023 (2)
2021 (2)

Study status

Recruiting (1)

Study type

RNA-seq of coding RNA (3)
RNA-seq of coding RNA from single cells (1)
RNA-seq of total RNA (1)
Interventional (1)

Release Date

2024 (9)
2022 (7)
2021 (7)
2023 (6)
2025 (4)
2026 (4)
2020 (4)

Lab affiliation

Department of Gynecological Oncology National Clinical Research Centre for Obstetrics and Gynecology Cancer Biology Research Centre (Key Laboratory of the Ministry of Education) Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology (1)
Molecular Oncology Moffitt Cancer Center Tampa, FL, USA (1)
Proteomics Core Facility University of Gothenburg Sweden (1)

Location

United States (1)

Keyword

Immunoconjugates (1)
Trastuzumab deruxtecan (1)
Trastuzumab (1)
Camptothecin (1)

Previous page
1 / 7
You're on page 1
page 2
page 3
page 4
page 5
page 6
page 7
Next page

Sort by:

Relevance

Page size

scRNA-seq of mouse immune compartment from tumours treated with ATRi ceralasertib (AZD6738)

PRJEB71928 | ENA

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Not available

S-EPMC10894296 | biostudies-literature

RNA-seq of neuroblastoma mouse model (Alk-F1178S Th-MYCN) after treatment with the ATR inhibitor ceralasertib

PRJEB62195 | ENA

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study.

Not available

S-EPMC12753540 | biostudies-literature

scRNA-seq of mouse immune compartment from tumours treated with ATRi ceralasertib (AZD6738)

Mice implanted with CT26 tumour cells were divided into two experimental groups (vehicle and ceralasertib) with the aim of assessing changes in intra-tumour T cells (CD3+) after 7 days of treatment with ceralasertib, and 7 days off. At the end of the treatment course, tumour tissue was isolated, ch...

ORGANISM(S): Mus musculus

2024-02-05 | E-MTAB-13713 | biostudies-arrayexpress

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Not available

S-EPMC10233611 | biostudies-literature

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.

Not available

S-EPMC9401487 | biostudies-literature

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

Not available

S-EPMC10786692 | biostudies-literature

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.